Revelation Biosciences Inc (REVB)

11:41 AM

REVB: New Target Market Announced - Research Tree

11:41 AM

09:00 AM

Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients - Yahoo Finance

09:00 AM

Apr 10, 2025

Why Revelation Biosciences Inc. (REVB) Went Down On Thursday? - Insider Monkey

Apr 10, 2025

Mar 21, 2025

Revelation Biosciences (REVB) to Release Earnings on Friday - Defense World

Mar 21, 2025

Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline - Investing.com

Mar 17, 2025

Mar 17, 2025

REVB stock touches 52-week low at $2.71 amid sharp annual decline By Investing.com - Investing.com South Africa

Mar 17, 2025

Mar 17, 2025

Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - Benzinga

Mar 17, 2025

Mar 17, 2025

Revelation Biosciences: Gemini priming attenuates inflammatory response in PBMCs - TipRanks

Mar 17, 2025

Mar 17, 2025

Gemini Priming Attenuates Inflammation In Human Peripheral Blood Mononuclear Cells - Marketscreener.com

Mar 17, 2025

Mar 17, 2025

Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells - Business Wire

Mar 17, 2025

Mar 13, 2025

Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference - Business Wire

Mar 13, 2025

Mar 10, 2025

What is Roth Capital’s Estimate for REVB FY2029 Earnings? - Defense World

Mar 10, 2025

Mar 07, 2025

REVB: 2025 Is the Year for Measurable Progress - Research Tree

Mar 07, 2025

Mar 06, 2025

Revelation Biosciences Inc. (REVB) reports earnings - Quartz

Mar 06, 2025

Mar 06, 2025

Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024 - WICZ

Mar 06, 2025

Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 By Investing.com - Investing.com South Africa

Feb 26, 2025

Feb 26, 2025

Revelation Biosciences stock hits 52-week low at $3.26 - Investing.com

Feb 26, 2025

Feb 26, 2025

Revelation Biosciences Doses First Patient In Prime Phase 1B Clinical Study Of Gemini In CKD Patients - Marketscreener.com

Feb 26, 2025

Feb 26, 2025

Revelation doses first patient in PRIME Phase 1b clinical study - TipRanks

Feb 26, 2025

Feb 26, 2025

Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Business Wire

Feb 26, 2025

Feb 26, 2025

Artificial Intelligence (AI) News Live Feed - StockTitan

Feb 26, 2025

Feb 24, 2025

Revelation Biosciences gets continued listing approval from Nasdaq - MSN

Feb 24, 2025

Feb 24, 2025

Revelation Biosciences Says Regained Compliance With Nasdaq Minimum Bid Price Requirement - marketscreener.com

Feb 24, 2025

Feb 24, 2025

Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval - Business Wire

Feb 24, 2025

Feb 24, 2025

Can This Biotech's New Kidney Disease Trial Transform CKD Treatment? Key Details - Stock Titan

Feb 24, 2025

Feb 13, 2025

Larchmont broker accused of years-long insider trading scheme - Westfair Communications

Feb 13, 2025

Feb 11, 2025

Allergic Rhinitis Market Expected to rise, 2034 | Regeneron, - openPR

Feb 11, 2025

Feb 03, 2025

Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews

Feb 03, 2025

Jan 30, 2025

Neumora Therapeutics, Rain Oncology, and Carmell Corporation: Stock Volatility Highlights Major Market Moves - HPBL

Jan 30, 2025

Jan 30, 2025

Allergic Rhinitis Market to Show Remarkable Growth Trends from - openPR

Jan 30, 2025

Jan 30, 2025

Revelation Biosciences stock hits 52-week low at $0.28 - MSN

Jan 30, 2025

Jan 29, 2025

REVB Start 1B Trial and Announces Split - MSN

Jan 29, 2025

Jan 29, 2025

REVB: Phase 1b Begins and Nasdaq Compliance Regained - Research Tree

Jan 29, 2025

Jan 28, 2025

Stock market news: MiNK Therapeutics -93.51%, Revelation Biosciences -93.45% among biggest losers during mid day trading - Business Upturn

Jan 28, 2025

Jan 28, 2025

Stock market news: Vincerx Pharma plunged by 95.86% while MiNK Therapeutics was down by 94.26% during mid day trading - Business Upturn

Jan 28, 2025

Jan 28, 2025

Stock market today: Revelation Biosciences -93.16%, MiNK Therapeutics -91.40% among biggest losers in early trading - Business Upturn

Jan 28, 2025

Jan 28, 2025

Stock market today: Vincerx Pharma declined by 95.75% whereas Revelation Biosciences - Business Upturn

Jan 28, 2025

Jan 28, 2025

Revelation Biosciences Inc (REVB) Has Strong Growth Prospects Through 2025 - Marketing Sentinel

Jan 28, 2025

Jan 27, 2025

Anthem man charged with insider trading - Foothills Focus

Jan 27, 2025

Jan 24, 2025

Revelation Biosciences stock hits 52-week low at $0.28 By Investing.com - Investing.com Canada

Jan 24, 2025

Jan 24, 2025

Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025 - BioSpace

Jan 24, 2025

Jan 24, 2025

Revelation Biosciences to effect 1-for-16 reverse stock split to regain Nasdaq compliance - MSN

Jan 24, 2025

Jan 21, 2025

Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients - Marketscreener.com

Jan 21, 2025

Jan 21, 2025

Revelation Bio Launches Phase 1b Trial of Gemini for Advanced Chronic Kidney Disease Treatment - Stock Titan

Jan 21, 2025

Jan 20, 2025

Florida Trader Among 4 Arrested for 7-Year-Long Insider Trading Scheme - NewsBreak

Jan 20, 2025

Jan 19, 2025

Revelation Biosciences (REVB) Price Target Increased by 242.79% to 40.04 - MSN

Jan 19, 2025